A phase I clinical trial of the anti-CD40 agonist (CDX-1140) alone or in combination with anti-PD-1 (pembrolizumab) is currently ongoing in solid cancers, including CCA [95]. The gene discussed is CD40; the disease is cholangiocarcinoma.